id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-E-1575-0007,FDA,FDA-2013-E-1575,Notice of Determination from U.S. Patent and Trademark Office to the FDA CDER,Other,Letter(s),2016-12-19T05:00:00Z,2016,12,2016-12-19T05:00:00Z,,2016-12-19T19:19:20Z,,0,0,0900006482427a55
FDA-2013-E-1575-0006,FDA,FDA-2013-E-1575,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2016-08-01T04:00:00Z,2016,8,2016-08-01T04:00:00Z,,2016-08-02T01:47:13Z,,0,0,090000648214b310
FDA-2013-E-1575-0005,FDA,FDA-2013-E-1575,"Determination of Regulatory Review Period for Purposes of Patent
Extension; RAXIBACUMAB",Notice,Determinations,2015-12-15T05:00:00Z,2015,12,2015-12-15T05:00:00Z,2016-02-17T04:59:59Z,2015-12-15T16:00:10Z,2015-31400,0,0,0900006481da7506
FDA-2013-E-1575-0004,FDA,FDA-2013-E-1575,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2015-11-18T05:00:00Z,2015,11,2015-11-18T05:00:00Z,,2015-11-18T14:36:12Z,,0,0,0900006481d50289
FDA-2013-E-1575-0003,FDA,FDA-2013-E-1575,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2014-01-31T05:00:00Z,2014,1,2014-01-31T05:00:00Z,,2014-01-31T16:48:01Z,,0,0,090000648153a167
FDA-2013-E-1575-0002,FDA,FDA-2013-E-1575,Human Genome Sciences Inc. (GlaxoSmithKline) - Patent Term Application,Other,Application,2013-12-05T05:00:00Z,2013,12,2013-12-05T05:00:00Z,,2013-12-05T15:59:43Z,,0,0,09000064814aa851
FDA-2013-E-1575-0001,FDA,FDA-2013-E-1575,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2013-12-05T05:00:00Z,2013,12,2013-12-05T05:00:00Z,,2013-12-05T15:46:34Z,,0,0,09000064814aa7f2